What is BSICoS?

The Biomedical Signal Interpretation and Computational Simulation (BSICoS) group focuses its activity on the processing, interpretation and Computer Simulation of biomedical signals.

The main objective of the group is the development of methods for biomedical signal processing, driven by the physiology, for personalized interpretation (diagnosis, prognosis and therapy) of the conditions of the cardiovascular, respiratory and autonomic nervous systems and their interactions.

The goal is to improve the impact of ICTs in health and further understanding the functioning of biological systems that can be observed through noninvasive signals. Key to this is working with clinical teams and research groups that combine the experiences of the two areas, direct research to solve relevant clinical problems and facilitate the transfer of results to clinical practice.

Imagen de una placa eléctrica

Research Lines

cardiac-pulse
Modeling and simulation of cardiac electrophysiology
heart
ECG markers for arrhythmia risk identification
electro
Processing of intracardiac EGM signals
Non-invasive parametrization of autonomic nervous system
Biomedical signal processing and characterization for respiratory pathologies
in-vitro-modelling
Experimental characterization and in-vitro modeling of cardiac aging
Long-term monitoring using wearable devices
brain computer
Neural interfaces with the central nervous system to study movement
Genetics of cardiovascular risk

News

Our PhD Students, Natalia Hernández and Marcos Sánchez, at the Gene and Cell Teraphy Congress and the Biennial Chemistry Meeting

Our PhD Students, Natalia Hernández and Marcos Sánchez, at the Gene and Cell Teraphy Congress and the Biennial Chemistry Meeting

Natalia Hernández Bellido: “Non-viral delivery of microRNA therapies for cardiac dysfunction using DNA nanostructures” Cardiac microRNAs (miRNAs) are dysregulated in cardiac disease and aging. Thanks to their pleiotropic effects, they are spotlighted as therapeutic targets to treat cardiac conditions. Nanotechnology enables targeted delivery of miRNA therapies, avoiding their low stability and potential off-target effects. Particularly, DNA nanostructures (DNS) for miRNA therapies have not yet been applied to cardiac disease. Our group has identified MIR24-2 upregulated with age in human left ventricle and miR24-2-5p to interact with genes essential in cardiac…

Read more
Back to top